In this study, we describe the oncogenic role of a novel long noncoding RNA (lncRNA) called LONA (LncRNA Overexpressed in NPM1 mutated Acute myeloid leukemia) overexpressed in patients with acute myeloid leukemia (AML) carrying the mutation of the nucleophosmin NPM1. The presence of the NPM1 mutant induces a delocalization from the cytoplasm towards the nucleus of the lncRNA LONA, which impacts its cellular functions. Gain and loss of function strategies have shown that LONA exerts opposite effects on myeloid differentiation depending on its subcellular localization by regulating the expression of crucial genes such as THBS1, ASB2 or MAFB. In vivo, overexpression of LONA reduces the survival of transplanted mice while its inactivation sensitizes them to treatment with cytarabine.

Discover the published article :

Leukemia. 2021 Jun 15:1-15.
A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
Gourvest M, De Clara E, Wu HC, Touriol C, Meggetto F, De Thé H, Pyronnet S, Brousset P, Bousquet M.

Key words :

  • Long noncoding RNA,
  • acute myeloid leukemia,
  • NPM1

Collaborations and acknowledgements

This work was funded by :

  • Fondation ARC pour la Recherche sur le Cancer
  • Association Laurette Fugain
  • Ligue Régionale Contre le Cancer (Comités de la Haute-Garonne, du Gers et de l’Aude)
  • LABEX TOUCAN
  • SFH (Société Française d’Hématologie).

Contact :

Marina Bousquet
Team CRCT : R’n Blood : RNA biology in hematological tumors
Mail : marina.bousquet@inserm.fr

en image